Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242282 | 1.00 | HDAC8 (0.44) | HDAC8HDAC6HDAC1SPHK1SPHK2 | |
| SCHEMBL13479297 | 0.87 | HRH3 (0.47) | HDAC8HDAC6HDAC1SPHK1SPHK2 | |
| SCHEMBL13343774 | 0.85 | ALDH1A1 (0.56) | HDAC8HDAC6HDAC1SPHK1SPHK2 | |
| SCHEMBL1189408 | 0.85 | OPRD1 (0.56) | SPHK1SPHK2OPRD1LTA4H | |
| SCHEMBL25824759 | 0.83 | MAPK1 (0.55) | HDAC8HDAC6HDAC1SPHK1SPHK2 | |
| SCHEMBL12891094 | 0.83 | HDAC8 (0.43) | HDAC8HDAC6HDAC1SPHK1SPHK2 | |
| SCHEMBL1189890 | 0.81 | OPRD1 (0.62) | KDM4EALDH1A1OPRD1 | |
| SCHEMBL26619347 | 0.81 | OPRD1 (0.62) | KDM4EALDH1A1OPRD1 | |
| SCHEMBL24108929 | 0.80 | HDAC8 (0.44) | HDAC8HDAC6HDAC1SPHK1SPHK2 | |
| SCHEMBL1242026 | 0.80 | SPHK1 (0.60) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | HDAC8 230/4885HDAC6 161/4885HDAC1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.